09

2020-05


R&D project

As a modern, health‑oriented technology enterprise, Minhai has amassed a wealth of core technologies across a diverse portfolio of vaccine products and research initiatives. The company maintains nearly 30 pipeline projects, broadly covering the world’s major vaccine categories, with a particularly enduring competitive edge in multivalent and combination vaccine platforms. Progress on key candidates—including a pentavalent vaccine, bivalent and quadrivalent influenza vaccines, and bivalent and quadrivalent inactivated enterovirus vaccines—is advancing steadily, establishing a robust “moat” of technological expertise and market performance. This lays a solid foundation for China’s biopharmaceutical industry to engage in high‑quality international competition and assume a central role on the global stage.

< 1 >